In contrast, stalling the UPR in the early phase by inhibiting GADD34 has been cytoprotective in other models, such as amyotrophic lateral sclerosis (ALS) and Charcot–Marie–Tooth disease (CMT). Here, PPP1R15A is linked to amyotrophic lateral sclerosis.